Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press17910.17650/1726-9776-2009-5-1-19-26DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫTHE SAFETY AND TOLERABILITY OF SORAFENIB IN THE TREATMENT OF EXTENSIVE RENAL CANCERОПЫТ ПРИМЕНЕНИЯ ТРЕХМЕРНОЙ ИНТРАОПЕРАЦИОННОЙ НАВИГАЦИИ ПРИ ЛАПАРОСКОПИЧЕСКОЙ АДРЕНАЛЭКТОМИИBiryukovV. A.ЕмельяновС. И.
Russian Federation
KaryakinO. B.ВередченкоВ. А.
Russian Federation
Medical Radiology Research Center, ObninskМГМСУ им. Н.А. Семашко3003200951192630072014https://oncourology.abvpress.ru/oncur/article/view/179

The performed study compared the toxic effects caused by the administration of sorafenib with the manifestations that immediately accompanied extensive renal-cell carcinoma. There is evidence that Sorafenib that is a safe and well tolerable agent increases progression-freesurvival.

 

Опыт применения трехмерной интраоперационной навигации при лапароскопической адреналэктомии

1. Strumberg D., Awada A., Hirte H. et al.Pooled safety analysis of BAY 43-9006(sorafenib) monotherapy in patients withadvanced solid tumours: is rash associatedwith treatment outcome? Eur J Cancer2006;42:548—56.Strumberg D., Awada A., Hirte H. et al.Pooled safety analysis of BAY 43-9006(sorafenib) monotherapy in patients withadvanced solid tumours: is rash associatedwith treatment outcome? Eur J Cancer2006;42:548—56.2. Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled random-ized discontinuation trial of sorafenib inpatients with metastatic renal cell carcino-ma. Clin Oncol 2006;24:2505—12.Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled random-ized discontinuation trial of sorafenib inpatients with metastatic renal cell carcino-ma. Clin Oncol 2006;24:2505—12.3. Escudier B., Eisen T., Sradler W.M. et al. Sorafenib in advanced clear-cellrenal-cell carcinoma. N Engl J Med2007;356:125—34.Escudier B., Eisen T., Sradler W.M. et al. Sorafenib in advanced clear-cellrenal-cell carcinoma. N Engl J Med2007;356:125—34.4. Nagore E., Insa A., Sanmartin O.Antineoplastic therapy-induced palmarplantar erythrodysesthesia («hand-foot»)syndrome. Incidence, recognition andmanagement. Am J Clin Dermatol2000;1:225—34.Nagore E., Insa A., Sanmartin O.Antineoplastic therapy-induced palmarplantar erythrodysesthesia («hand-foot»)syndrome. Incidence, recognition andmanagement. Am J Clin Dermatol2000;1:225—34.5. Robert C., Soria J.C., Spatz A. et al.Cutaneous sides of kinase inhibitors andbloking antibodies. Lancet Oncol2005;6:491—500.Robert C., Soria J.C., Spatz A. et al.Cutaneous sides of kinase inhibitors andbloking antibodies. Lancet Oncol2005;6:491—500.6. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa inmetastatic renal-cell carcinoma. N Engl JMed 2007;356:115—24.Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa inmetastatic renal-cell carcinoma. N Engl JMed 2007;356:115—24.